Header Logo

Connection

Francesca CONRADIE to Anti-HIV Agents

This is a "connection" page, showing publications Francesca CONRADIE has written about Anti-HIV Agents.
Connection Strength

1,076
  1. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):73-78.
    View in: PubMed
    Score: 0,333
  2. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
    View in: PubMed
    Score: 0,083
  3. Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
    View in: PubMed
    Score: 0,072
  4. Cutting the cost of South African antiretroviral therapy using newer, safer drugs. S Afr Med J. 2016 Dec 21; 107(1):28-30.
    View in: PubMed
    Score: 0,072
  5. Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. AIDS Res Hum Retroviruses. 2013 Oct; 29(10):1287-92.
    View in: PubMed
    Score: 0,057
  6. Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. Clin Infect Dis. 2012 May; 54 Suppl 4:S261-5.
    View in: PubMed
    Score: 0,052
  7. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,051
  8. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,051
  9. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
    View in: PubMed
    Score: 0,050
  10. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS. 2011 Feb 20; 25(4):479-92.
    View in: PubMed
    Score: 0,048
  11. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
    View in: PubMed
    Score: 0,048
  12. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012 Feb; 41(1):43-54.
    View in: PubMed
    Score: 0,047
  13. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
    View in: PubMed
    Score: 0,043
  14. Integration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic Syndr. 2006 Dec 15; 43(5):577-81.
    View in: PubMed
    Score: 0,036
  15. Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1106-1111.
    View in: PubMed
    Score: 0,019
  16. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14; 363(16):1499-509.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.